Advisors Asset Management’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
Other funds holding SMMT
BBA
KCM
Advisors Asset Management's SMMT Position: Q3 2026 in Review
Advisors Asset Management sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 11,123 shares — an estimated $162K sold.
Advisors Asset Management first reported a position in SMMT in Q4 2024 and held it in 7 quarters. The position peaked at $238K in Q2 2025. 295 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.
- Advisors Asset Management reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
- Advisors Asset Management sold 11,123 Summit Therapeutics shares in Q3 2026, an estimated $162K.
- Advisors Asset Management first reported a position in Summit Therapeutics in Q4 2024 and held it in 7 quarters.
- Advisors Asset Management's Summit Therapeutics position peaked at $238K in Q2 2025.
- 295 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.
Based on Advisors Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.